Obermatt
See Similar Stocks →

ARS Pharmaceuticals

NMQ:SPRY · US82835W1080
BiotechnologySmall

360

32
Profit price33
Owner Earnings Yield1
Dividend Yield1
Price/Sales56
EV / Gross Profit24
Price/Book91
Return on Capital21
Cash Return on Capital7
Return on Equity7
EBIT Margin6
Gross Profitability56
Accruals72
Owner Earnings Margin29
Sales growth78
Profit growth42
Reinvestment31
Price momentum16
Debt load14
Refinancing49
Debt Payback1
Liquidity22
Analyst ratings100
Opinion Changes4
Price Target Upside88
Market mood98
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ARS Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Employees147
Websitears-pharma.com
ISINUS82835W1080
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
AllergyBiopharmaPharmaceutical

Description

ARS Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company focuses on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions,…

Analysis

Middle-of-the-road

ARS Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
18
2026

All-time high

23

Mar 2026

All-time low

18

Jun 2026

Average rank

21

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
56
—
—
—
Price/Earnings
61
—
—
—
Price/Book
91
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
76
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ARS Pharmaceuticals with its peers
Ardelyx
NMQ:ARDX
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Verastem
NAQ:VSTM
56
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vanda Pharmaceuticals
NMQ:VNDA
58
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
TG Therapeutics
NAQ:TGTX
77
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Puma Biotechnology
NSQ:PBYI
79
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →